Biologics Manufacturing Intelligence
Expert analysis and strategic insights for biopharmaceutical outsourcing decisions
Navigate the evolving biologics landscape with in-depth reporting on CDMO capabilities, manufacturing trends, and strategic outsourcing insights from industry experts.
Executive Interview
Building a World-Class Biologics CDMO from the Ground Up
An exclusive conversation with the CEO of BORA Pharmaceuticals
BORA Pharmaceuticals CEO shares a candid look at scaling biologics manufacturing capabilities, navigating global regulatory landscapes, and the strategic vision driving BORA’s rapid expansion into one of the most trusted CDMOs in the Asia-Pacific region and beyond.
“Our mission has always been to provide the highest quality manufacturing while remaining agile enough to serve emerging biotechs and global pharma alike.”
— CEO, BORA Pharmaceuticals
“Connecting biopharma leaders with the insights, partners, and strategies they need to succeed.”
Featured Consultant
Expert Advisory Services
Top-Rated Consultant 2026
Myrna Monck
Senior Biologics Manufacturing Consultant
30+
Years Experience
75+
Companies Advised
$2B+
Years Experience
Myrna is a recognized authority in biologics manufacturing strategy with three decades of experience spanning Big Pharma and emerging biotech. She specializes in CDMO selection, technology transfer optimization, and manufacturing network strategy. Previously VP of External Manufacturing at a top-10 pharma company, Myrna has led outsourcing programs worth over $2 billion.
Areas of Expertise
Request Consultation
Ask a Question
Featured CDMO
BORA Pharmaceuticals — Company Walkthrough
BORA Pharmaceuticals has emerged as a leading CDMO partner for biologics, offering end-to-end manufacturing services from process development through commercial-scale production. With state-of-the-art facilities across Asia and North America, BORA serves sponsors ranging from virtual biotechs to global pharma.
2004
Founded
3,500+
Employees
Core Capabilities
Process Development
Cell line to IND-enabling
Clinical Manufacturing
Phase I–III cGMP production
Commercial Scale
Large-scale biologics supply
Analytical Services
Full characterization suite
Featured Laboratory
Cicadea Biologics — Analytical Excellence
Cicadea Biologics is a specialized analytical laboratory delivering critical quality testing and characterization services for the biologics industry. Their team of experienced scientists supports clients from early development through commercial product release, ensuring regulatory compliance across global markets.
Comprehensive biologics characterization (SEC, CE-SDS, icIEF, peptide mapping)
Stability testing programs (ICH-compliant, accelerated, stress studies)
Cell-based potency assays and bioassay development
Method development, validation, and technology transfer support
Method development, validation, and technology transfer support
View Lab Profile →
Request Services
Samsung Biologic’s $2.3B Expansion Reshapes Asian CDMO Landscape
New inspection protocols and documentation requirements reshape compliance expectations.
EU Regulators Signal Stricker CDML Oversight for 2026
New inspection protocols and documentation requirements reshape compliance expectations.
Cell & Gene Therapy Manufacturing: U.S. Capacity Looms
Demand outpaces supply as dozens of therapies approach commercialization milestones.
Latest Biologics Articles
TECHNOLOGY
Single-Use Systems Gain Momentum in mAB Production
The Roll of AI in Biologies Quality Control
Scaling Cell Therapy Manufacturing: Current Challenges
Final-Finish Capacity: Where Are The Bottlenecks?
ADC
ADC Manufacturing: Payload-Linker Trends for 2026
Tech Transfers Best Practices For Biologics Programs
Biosimilars Manufacturing Economies Explaines
mRNA Manufacturing Scale-Up Lessons Learned